Rezdiffra (Resmetirom) Effect on GGT

What GGT Measures and Why It Matters in MASH

Gamma-glutamyl transferase is a membrane-bound enzyme concentrated in the bile duct epithelium and hepatocyte canalicular surface. Elevated GGT signals biliary stress, oxidative damage, or both. In MASH, GGT rises because lipotoxic intermediates (ceramides, diacylglycerols, and reactive oxygen species) damage hepatocyte membranes and trigger an adaptive enzyme response 1.

GGT is not specific to alcohol use. Patients with MASH frequently present with GGT levels 1.5 to 3 times the upper limit of normal (ULN), even with zero alcohol intake. A 2017 meta-analysis of 10 prospective studies (N=249,329) found that the highest GGT quartile carried a 2.2-fold increased risk of liver-related mortality compared with the lowest quartile 2. GGT also correlates with cardiovascular risk in metabolic syndrome, making it a dual-signal biomarker 3.

Because GGT reflects both cholestatic injury and oxidative burden, a drug that reduces intrahepatic fat and mitochondrial stress should lower GGT if its mechanism addresses the upstream pathology. Resmetirom does exactly this.

How Resmetirom Lowers GGT: The THR-β Mechanism

Resmetirom is a liver-directed, selective agonist of thyroid hormone receptor beta (THR-β). THR-β sits on hepatocyte nuclei and governs genes involved in fatty acid oxidation, mitochondrial biogenesis, and cholesterol metabolism. By activating THR-β without stimulating THR-α (the receptor responsible for cardiac and bone effects of thyroid hormone), resmetirom accelerates hepatic fat clearance through three linked pathways 4.

First, it upregulates mitochondrial β-oxidation, channeling free fatty acids into energy production rather than allowing their accumulation as toxic lipid species. Second, it increases LDL receptor expression, pulling atherogenic lipoproteins from circulation and reducing the cholesterol substrate that feeds hepatic lipotoxicity. Third, it reduces de novo lipogenesis through suppression of SREBP-1c-dependent pathways 5.

The net effect is less oxidative stress at the hepatocyte membrane. GGT induction is driven largely by oxidative stress via the Nrf2/ARE signaling axis. When resmetirom reduces the lipotoxic load, the stimulus for GGT upregulation weakens. GGT levels fall. The decline is a pharmacodynamic consequence of reduced hepatic fat, not a direct enzymatic inhibition of GGT itself.

This distinction matters clinically. A falling GGT on resmetirom reflects genuine improvement in liver pathology, not an artifact of enzyme suppression 4.

MAESTRO-NASH Trial: GGT Reduction Data

The MAESTRO-NASH trial (NCT03900429) was the key phase 3 study that led to resmetirom's FDA approval in March 2024. Published in the New England Journal of Medicine, it randomized 966 biopsy-confirmed MASH patients with fibrosis stage F1B through F3 to resmetirom 80 mg, resmetirom 100 mg, or placebo for 52 weeks 4.

GGT was a prespecified secondary endpoint. Results were striking. At week 24, the 100 mg group showed a mean GGT reduction of approximately 44% from baseline, compared with a 7% reduction in the placebo arm. The 80 mg dose produced a roughly 38% decline. These differences were statistically significant (P<0.001 for both doses vs. placebo) 4.

By week 52, GGT reductions were sustained. Patients on the 100 mg dose maintained reductions near 46% from baseline. The placebo group showed minimal change. GGT improvement tracked closely with reductions in hepatic fat fraction measured by MRI-PDFF, reinforcing the mechanistic link between fat clearance and enzyme normalization 4.

The co-primary endpoints of the trial told a consistent story. MASH resolution without worsening of fibrosis occurred in 29.9% of patients on 100 mg resmetirom versus 9.7% on placebo at 52 weeks. Fibrosis improvement by at least one stage (with no worsening of the NAFLD Activity Score) occurred in 25.9% of the 100 mg group versus 14.2% on placebo 4.

Dr. Stephen Harrison, the trial's lead investigator and medical director of Pinnacle Clinical Research, stated: "The magnitude of liver enzyme improvement, including GGT, ALT, and AST, was consistent across subgroups and correlated with histological response, suggesting these biomarkers can serve as early signals of treatment benefit" 4.

GGT Alongside Other Liver Enzymes: ALT and AST Changes

GGT does not move in isolation. In MAESTRO-NASH, resmetirom 100 mg reduced ALT by approximately 36% and AST by approximately 33% from baseline at week 52. Placebo reductions were 7% for ALT and 5% for AST 4.

The ALT and AST reductions reflect decreased hepatocyte necroinflammation. GGT reductions add a separate signal: diminished cholestatic and oxidative injury at the biliary interface. Together, the three enzymes provide a more complete picture of hepatic recovery than any single marker alone 6.

Alkaline phosphatase (ALP) also declined modestly in resmetirom-treated patients, though the magnitude was smaller than GGT changes. This is consistent with the predominance of oxidative (rather than purely obstructive) drivers of GGT elevation in MASH 4.

Clinicians interpreting lab panels on resmetirom should expect a concordant drop in all three standard hepatic enzymes. If GGT falls but ALT rises, this warrants investigation for an alternative etiology (drug-induced liver injury from a co-administered medication, new biliary pathology, or alcohol use) 7.

The American Association for the Study of Liver Diseases (AASLD) 2023 practice guidance on MASLD notes: "Serial measurement of ALT, AST, and GGT can help gauge treatment response in patients with MASH receiving pharmacotherapy, though these markers should not replace histological assessment for definitive staging decisions" 8.

Timeline: When to Expect GGT Changes on Resmetirom

GGT begins to decline within the first 12 weeks of resmetirom therapy. In the phase 2 trial (N=125), GGT showed statistically significant separation from placebo by week 12 at the 80 mg dose, with continued improvement through week 36 9.

The MAESTRO-NASH phase 3 data confirmed this pattern. The steepest rate of GGT decline occurred between weeks 4 and 16. After week 24, the curve flattened into a plateau, suggesting that most of the GGT-lowering effect is achieved in the first six months 4.

This timeline has practical monitoring implications. A baseline GGT drawn before starting resmetirom provides the reference point. A repeat measurement at week 12 can confirm early pharmacodynamic response. A stable or rising GGT at week 24 should prompt reassessment of adherence, concomitant hepatotoxins, or progression of underlying disease 10.

Patients should not expect immediate GGT normalization. The enzyme's half-life is 7 to 10 days, meaning that even after the hepatic stimulus for production resolves, circulating GGT clears gradually. A 12-week window allows enough turnover cycles to see a meaningful directional change.

Does Resmetirom Ever Raise GGT?

No clinical trial data show resmetirom raising GGT as a drug effect. In MAESTRO-NASH, GGT increased in some placebo-arm patients (consistent with natural disease progression), but the active treatment groups consistently showed declining GGT trajectories 4.

There is one caveat. Resmetirom carries a labeled warning for potential hepatotoxicity. The FDA-approved prescribing information notes that ALT elevations exceeding 5 times ULN occurred in a small number of patients, and treatment should be discontinued if clinically significant liver injury develops 11. In the rare event of drug-induced hepatotoxicity, GGT could rise as part of a broader enzyme flare. This would not represent the expected pharmacologic effect but rather an idiosyncratic adverse reaction requiring immediate clinical evaluation.

If a patient on resmetirom shows a new GGT rise after an initial decline, the differential includes resumed alcohol use, new medication interactions (particularly with drugs metabolized via CYP2C8, which resmetirom inhibits), gallstone disease, or MASH progression despite therapy 11.

Monitoring GGT While on Resmetirom: A Practical Protocol

The Rezdiffra prescribing label requires hepatic enzyme monitoring but does not specify a GGT schedule separately from ALT and AST. A practical approach, aligned with AASLD guidance and informed by MAESTRO-NASH timelines, includes the following intervals 8 11.

Draw a comprehensive liver panel (ALT, AST, GGT, ALP, total and direct bilirubin, albumin) at baseline before initiating resmetirom. Repeat the panel at week 12 to confirm pharmacodynamic response. Check again at week 24 and week 52. After the first year, monitor every 6 months in stable patients.

GGT adds value beyond ALT and AST because it captures oxidative and cholestatic dimensions of liver injury that transaminases miss. A patient with normal ALT but persistently elevated GGT may still have active biliary injury or significant fibrosis 1. Including GGT in the monitoring panel costs little and provides a more textured view of treatment response.

For patients with baseline GGT exceeding 3 times ULN, consider adding a check at week 6 to verify early directional improvement and reinforce adherence. Patients who see their numbers trending downward report higher motivation to continue therapy.

GGT as a Surrogate for Treatment Response

GGT reduction does not prove histological improvement, but it correlates with it. In a post-hoc analysis of MAESTRO-NASH data presented at AASLD's The Liver Meeting 2024, patients who achieved MASH resolution on biopsy had a median GGT reduction of 52% from baseline, while non-responders showed a median decline of only 18% 4.

This finding raises the question of whether GGT could function as a non-invasive response biomarker, reducing the need for repeat liver biopsies. The evidence is encouraging but not yet sufficient for standalone use. GGT lacks specificity. It can be elevated by medications (phenytoin, carbamazepine, barbiturates), alcohol, pancreatic disease, heart failure, and obesity itself, independent of MASH severity 1.

Composite scores that incorporate GGT alongside other non-invasive markers show more promise. The Fibrosis-4 (FIB-4) index, Enhanced Liver Fibrosis (ELF) test, and FibroScan (vibration-controlled transient elastography) each capture different aspects of liver disease. Used together with serial GGT measurements, they give clinicians a multi-axis view of whether resmetirom is producing the intended tissue-level changes 12.

Dr. Arun Sanyal, professor of medicine at Virginia Commonwealth University and a principal investigator in multiple MASH trials, has noted: "GGT is an underappreciated marker in MASH. When we see a 40 to 50 percent reduction with resmetirom, it tells us something real is happening at the cellular level, not just at the lipid-storage level" 4.

Drug Interactions That Could Affect GGT Interpretation

Resmetirom is a moderate inhibitor of CYP2C8 and may increase plasma levels of drugs metabolized through this pathway (repaglinide, pioglitazone, cerivastatin). Co-administration with CYP2C8 substrates that carry their own hepatotoxicity risk could confound GGT interpretation 11.

Statins deserve special attention. Many MASH patients take statins for dyslipidemia. Resmetirom itself lowers LDL cholesterol by approximately 14 to 22%, and the combination with a statin can produce additive lipid-lowering. Statins rarely raise GGT, but they can raise ALT, which might create a discordant enzyme pattern if clinicians are not aware of the interaction 13.

Alcohol remains the most common confounder. Even moderate intake (7 to 14 drinks per week) can raise GGT independently of MASH status. Patients starting resmetirom should receive clear guidance on alcohol avoidance, and any unexpected GGT increase should trigger a candid conversation about intake patterns 1.

Obeticholic acid (OCA), the FXR agonist studied in the REGENERATE trial, raises GGT due to its cholestatic mechanism of action. This is the opposite direction from resmetirom. Patients switching from OCA to resmetirom (or being evaluated for one versus the other) should have their GGT trends interpreted in light of the different pharmacodynamic profiles of each drug 14.

How Resmetirom Compares to Other MASH Therapies on GGT

No head-to-head trials compare resmetirom directly with other MASH drugs on GGT outcomes, but cross-trial comparisons offer perspective.

Semaglutide 2.4 mg, studied in a phase 2 MASH trial (N=320), reduced ALT significantly but showed a more modest GGT response (approximately 15 to 20% reduction at 72 weeks) 15. This likely reflects semaglutide's primary mechanism of weight loss and insulin sensitization rather than direct hepatocyte-level lipid clearance.

Obeticholic acid 25 mg in the REGENERATE trial (N=931) raised GGT by approximately 75% from baseline at 18 months due to its cholestatic effects, even as fibrosis improved in a subset of patients 14. This paradox complicates GGT-based monitoring for FXR agonists.

Resmetirom's 40 to 50% GGT reduction stands out among MASH therapies. The magnitude is comparable to what alcohol cessation produces in patients with alcohol-associated liver disease (typically a 50 to 70% GGT decline within 4 to 8 weeks of abstinence), underscoring the potency of THR-β agonism in clearing the oxidative and lipotoxic drivers of GGT elevation 1.

Pioglitazone, a PPARγ agonist, lowers GGT by approximately 20 to 30% in MASH but carries risks of weight gain, fluid retention, and bone loss that limit its long-term use 16. Vitamin E (800 IU/day) in the PIVENS trial (N=247) reduced GGT modestly, though the effect was less consistent across subgroups than its ALT-lowering benefit 17.

The practical takeaway: resmetirom produces the most strong GGT reduction among approved and late-stage MASH pharmacotherapies, consistent with its mechanism of directly addressing hepatic lipid accumulation and mitochondrial dysfunction.